NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

Phase 1

Completed

Conditions: HIV, Inflammation

Interventions: Drug: Assess Safety
Drug: Effect of drug on viral load
Drug: Effect of drug on T-cell count
Drug: Effect of drug on inflammatory biomarkers

First Posted Date: 2016-01-12

Last Posted Date: 2018-11-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 38

Registration Number: NCT02652546

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifapentine (RPT)
Drug: Isoniazid (INH)
Dietary Supplement: Pyridoxine (vitamin B6)

First Posted Date: 2016-01-08

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT02651259

Locations: 🇿🇼
Harare Family Care CRS, Harare, Zimbabwe
🇲🇼
Malawi CRS, Lilongwe, Central Malawi, Malawi
🇭🇹
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti

and more 2 locations

Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali

Completed

Conditions: Accute Falciparum Malaria

First Posted Date: 2016-01-05

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 154

Registration Number: NCT02645604

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa

Phase 2

Terminated

Conditions: Loiasis

Interventions: Drug: Imatinib Mesylate
Drug: Placebo

First Posted Date: 2016-01-01

Last Posted Date: 2022-06-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT02644525

Locations: 🇨🇲
Centre de Recherche sur les Filarioses et Autres Maladies Tropicales, Mbalmayo, Cameroon

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

Recruiting

Conditions: Malaria

First Posted Date: 2015-12-24

Last Posted Date: 2024-12-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1500

Registration Number: NCT02639299

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CLAD Phenotype Specific Risk Factors and Mechanisms

Completed

Conditions: Post Lung Transplantation
Lung Transplant

Interventions: Procedure: Blood Draw
Procedure: Bronchoscopy

First Posted Date: 2015-12-16

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 884

Registration Number: NCT02631720

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 2 locations

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru

Not Applicable

Completed

Conditions: RNA Virus Infections
Acquired Immunodeficiency Syndrome
Sexually Transmitted Diseases
Retroviridae Infections
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Infections
Lentivirus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral

Interventions: Procedure: Circumcision
Procedure: Flexible sigmoidoscopy

First Posted Date: 2015-12-15

Last Posted Date: 2015-12-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 29

Registration Number: NCT02630082

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Phase 1

Active, not recruiting

Conditions: Chronic Granulomatous Disease Transplant

Interventions: Drug: Alemtuzumab
Drug: Busulfan
Drug: Sirolimus
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Biological: Peripheral blood stem cells

First Posted Date: 2015-12-14

Last Posted Date: 2024-12-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT02629120

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cardiometabolic Effects of Eplerenone in HIV Infection

Phase 2

Terminated

Conditions: Hepatic Steatosis
Cardiac Steatosis

Interventions: Drug: Inspra /Eplerenone

First Posted Date: 2015-12-14

Last Posted Date: 2018-07-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT02629094

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Biological: PfSPZ Challenge Material
Other: Normal Saline
Drug: PBS and HSA Diluent
Drug: ASAQ
Drug: Coartem

First Posted Date: 2015-12-11

Last Posted Date: 2021-04-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 409

Registration Number: NCT02627456

Locations: 🇲🇱
University of Bamako (USTTB/MRTC), Bamako, Mali

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy